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Abstract
Purpose: With the move towards magnetic resonance imaging (MRI) as a primary
treatment planning modality option for men with prostate cancer, it becomes criti-
cal to quantify the potential uncertainties introduced for MR‐only planning. This
work characterized geometric and dosimetric intra‐fractional changes between the
prostate, seminal vesicles (SVs), and organs at risk (OARs) in response to bladder
filling conditions.
Materials and methods: T2‐weighted and mDixon sequences (3–4 time points/sub-
ject, at 1, 1.5 and 3.0 T with totally 34 evaluable time points) were acquired in nine
subjects using a fixed bladder filling protocol (bladder void, 20 oz water consumed
pre‐imaging, 10 oz mid‐session). Using mDixon images, Magnetic Resonance for Cal-
culating Attenuation (MR‐CAT) synthetic computed tomography (CT) images were
generated by classifying voxels as muscle, adipose, spongy, and compact bone and by
assignment of bulk Hounsfield Unit values. Organs including the prostate, SVs, blad-
der, and rectum were delineated on the T2 images at each time point by one physi-
cian. The displacement of the prostate and SVs was assessed based on the shift of
the center of mass of the delineated organs from the reference state (fullest bladder).
Changes in dose plans at different bladder states were assessed based on volumetric
modulated arc radiotherapy (VMAT) plans generated for the reference state.
Results: Bladder volume reduction of 70 ± 14% from the final to initial time point
(relative to the final volume) was observed in the subject population. In the empty
bladder condition, the dose delivered to 95% of the planning target volume (PTV)
(D95%) reduced significantly for all cases (11.53 ± 6.00%) likely due to anterior
shifts of prostate/SVs relative to full bladder conditions. D15% to the bladder
increased consistently in all subjects (42.27 ± 40.52%). Changes in D15% to the rec-
tum were patient‐specific, ranging from −23.93% to 22.28% (−0.76 ± 15.30%).
Conclusions: Variations in the bladder and rectal volume can significantly dislocate
the prostate and OARs, which can negatively impact the dose delivered to these
organs. This warrants proper preparation of patients during treatment and imaging
sessions, especially when imaging required longer scan times such as MR protocols.
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1 | INTRODUCTION
Prostate cancer is the most common type of cancer in men, with
over 160 000 cases reported in 2017 in the United States.1 The cur-
rent treatment‐planning workflow involves using computed tomogra-
phy simulation (CT‐SIM) as the primary planning modality. However,
magnetic resonance imaging (MRI) has been shown to show superior
accuracy to CT for identifying the prostate gland, the prostatic apex,
and areas of high tumor burden.2–6 By performing an MRI to CT
rigid registration, the prostate can be delineated on MRI and then
transferred to CT for subsequent planning. This co‐registration may
introduce uncertainties of 2–3 mm for prostate cancer.7–9 Recently,
as a means to circumvent this uncertainty and streamline the clinical
workflow, MR‐only planning has emerged in the clinic. For the male
pelvis, two MR‐only packages are currently clinically available for
prostate cancer treatment planning with synthetic CTs [synCTs, or
CTs generated from MRI input(s)]. One FDA‐approved software
package, the Philips Magnetic Resonance for Calculating Attenuation
(MR‐CAT), is based on a dual echo three‐dimensional (3D) mDixon
fast field echo sequence with synCTs generated on the scanner.10,11
In a recent study by Farjam et al.,12 pelvic MR‐CAT images of 23
patients with prostate cancer underwent deformable registration to
the planning CT images and found good overall agreement over the
entire pelvis volume [mean absolute error (MAE) values of
65 ± 5 HU] with even smaller difference observed in the fat and
muscle (~40 HU) across all subjects. However, it is not currently
known how synthetic CT generation performs over a variety of
internal conditions nor has the dosimetric impact of this been char-
acterized. The other MR‐only package (Spectronic's MriPlanner) is
regulatory approved (CE‐marked), and creates synCT images based
on a statistical decomposition algorithm (SDA) from a single T2‐
weighted dataset.13 Comparison of the synCT and CT‐based dose
plans for prostate showed <1% difference in the mean absorbed
dose to the PTV for the MR‐CAT14 and 0.0 ± 0.2% for the SDA
methods.13
It has been shown that substantial variations in the bladder vol-
ume occur during the course of treatment.15,16 Importantly, the
variations in the bladder filling adversely impact the dose delivered
to the prostate over a standard course of radiotherapy for the
prostate.17,18 Huang et al.19 used daily cone‐beam computer tomog-
raphy (CBCT) images to measure target/organ volumes and dosimet-
ric differences in 28 prostate cancer patients and found mean
percentage volume differences of 44% within the bladder volumes
in the treatment plan which led to percentage dose difference of
2 ± 2% in the prostate.
As MRI emerges as a primary treatment planning modality option
for prostate cancer,20 it becomes important to quantify the potential
uncertainties introduced in an MR‐only workflow due to variable
physiological status that may confound accurate dosimetry and high‐
precision radiation therapy. One of the main issues that arises with
MRI is the longer scanning times as compared to CT, which may lead
to higher variations in the bladder and rectal volumes. It is currently
unknown how robust MR‐only treatment planning is to internal anat-
omy changes nor how the dosimetry may be impacted. This work
characterizes the temporal, spatial, and dosimetric intra‐fractional
changes between the prostate, seminal vesicles (SVs), and other
organs at risk (OARs) in response to bladder filling conditions for
MR‐only prostate cancer radiation therapy planning.
2 | MATERIALS AND METHODS
2.A | Subjects and bladder filling protocol
Nine healthy male volunteers (Age: 43 ± 10.1 yr (range: 25–61 yr);
Weight: 78.8 ± 9.6 kg) were recruited and consented to being
scanned at one of the three different magnetic field strengths (1.0, 1.5
or 3.0 T). Three volunteers were scanned using a large, rigid 8‐element
phased array coil on a 1.0 T Panorama High Field Open Magnetic Res-
onance System (Philips Medical Systems, Cleveland, OH) equipped
with flat table‐top (Civco, Orange City, IA) and external laser system as
described previously.21 Three other healthy male volunteers were
scanned at 1.5 T (Philips Achieva with 32‐element torso coil), and the
last three on a 3.0 T (Philips Ingenia with integrated posterior 32‐ele-
ment coil and anterior array) scanner with standard concave table‐
tops. Pelvic MR images were acquired according to a bladder filling
protocol with the patient in a supine position (Fig. 1). Prior to imaging,
each subject voided their bladder and consumed 20 oz of water. The
first acquisition represented an empty bladder state. An additional 10–
20 oz of water was consumed without subject repositioning before 1–
2 intermediate states were acquired, and a final full bladder acquisition
was performed. Due to longer scan times at low magnetic fields for
1 T experiments, imaging was possible at only three time points during
the ~45 min imaging session; but at 1.5 and 3 T, shorter acquisition
times allowed image acquisition at three to four time points for each
subject. Overall, a total of 34 evaluable time points were analyzed for
the entire cohort.
2.B | Imaging protocol
T2‐weighted turbo spin echo images were acquired since it is the
most commonly used image for delineation of organs in the pelvis.22
The imaging protocol also consisted of dual echo 3D FFE (Fast Field
Echo) mDIXON sequences11 which were optimized for acquisition at
each field strength (3T: TR/TE1/TE2 = 3.83/1.23/2.4 ms, Voxel Size =
1.45 × 1.45 × 0.23 mm, BW = 1072 Hz; 1.5 T: TR/TE1/TE2 = 6/
1.78/4 ms, Voxel Size = 1.45 × 1.45 × 0.28 mm, BW=541 Hz; 1 T:
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TR/TE1/TE2 = 15.87/6.9/13.81 ms, Voxel Size = 1.41 × 1.41 × 0.74
mm, BW = 975 Hz). The mDixon scan is designed to yield high‐geo-
metric accuracy by using short echo times and high bandwidth. The
advantage of using the two echoes in the mDIXON approach is to
allow water, fat, and in‐phase images to be derived within the same
acquisition by using the frequency shift of the fat and water pro-
tons.11 These images are inputted into the MR‐CAT software to pro-
duce the Synthetic CT image used for treatment planning.10 Briefly,
MR‐CAT automatically segments the external anatomy from back-
ground air using the water and in‐phase images. Next, a model‐based
segmentation method is used to segment bone from the external
contour based on training datasets.11 Soft tissue is defined as voxels
within the body volume and outside the segmented bone.10,11,23 An
intensity‐based classification is then used to segment adipose and
muscle within the soft tissue using the water and fat images. Finally,
the bone voxels are divided into compact and spongy bone based on
the voxel intensity of the in‐phase image. In summary, MR‐CAT cate-
gorizes the contents of the MR images into five classes (air, fat,
water‐rich tissue, spongy bone, and compact bone) and assigns to
each voxel a bulk Hounsfield Unit value based on its classification,
and the final synCT image is generated for treatment planning.11
One current limitation of MR‐CAT is that it does not account for
rectal gas in the image classification. To fully elucidate the dosimetric
impact of bladder and rectal status changes, the intestinal gas
with each rectal contour was automatically thresholded and
assigned a CT value of −350 HU based on values obtained from the
literature.24
2.C | Volumetric and geometric analysis
The prostate, SVs, bladder, and rectum were delineated on the T2‐
weighted images by a single physician in the Eclipse Treatment Plan-
ning System (Version 11.0,Varian Medical Systems, Palo Alto, CA).
Boolean operations were used to generate the proximal 1 cm of the
SVs (proxSVs) and the planning target volume (PTV) consisting of
the prostate and proxSVs with a 1 cm expansion in all directions
except posteriorly, which was expanded 0.6 cm. Overall, 170 evalu-
able contours were delineated in this study. For each volunteer, ini-
tial and intermediate T2‐weighted images of each subject and their
corresponding contours were rigidly registered to the T2‐weighted
image of the final time point (image with the largest bladder volume)
using three parameter translation with mutual information as the
cost function and nearest neighbor interpolation in FSL (FMRIB Soft-
ware Library, Wellcome Center, Oxford, UK). This step ensured
matching of the bony structures as the fixed components of the
images across different time points as well as isolation of local
effects such as possible movement (displacement) during the imaging
period.
Next, for each time point, the contours of each organ were con-
verted into a solid three‐dimensional volume using MATLAB
(MATLAB R2016b, The MathWorks, Inc., Natick, MA, USA). The cen-
ter of mass (COM) coordinates for each organ was calculated by
finding the mean coordinates of all voxels of the volume along each
major axis. The displacement of each organ was defined as the COM
shift relative to the final time point.
2.D | Dosimetric analysis
Using MR‐CAT images of the last time point (i.e., full bladder, which
is consistent with our clinical practice), volumetric modulated arc
radiotherapy (VMAT) plans were generated using two full arc beams
with 6 MV photons. The treatment planning was designed to deliver
79.2 Gy to the PTV using RTOG 0815 dose constraints as a guide-
line.25 Next, plans were copied and recalculated to the synCTs of
the other time points using fixed monitor units from the full bladder
plans. After all the plans were created for each subject, an auto-
mated MATLAB program parsed the dose volume histograms (DVHs)
in Eclipse and dosimetric data were tabulated for several dose
F I G . 1 . Bladder filling protocol. The
highlighted planning target volume (PTV)
can be seen based on the delineation of
the prostate at the last time point. Effects
of changes in the bladder volume can be
seen in earlier time points where the shift
of the prostate leads the PTV contour to
overlap with the rectum as the bladder
gets smaller in volume.
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metrics for the PTV and OARs according to QUANTEC recom-
mended endpoints.26–28
2.E | Statistical analysis
Repeated measures mixed models containing fixed (time points) and
random (subjects) effects were used to assess the significance of
changes of dose at different bladder states (initial, middle, and final)
while using the multiple/repeated measures on the same subject. If
the effect of the bladder states was significant (P < 0.05), pairwise
comparisons of three time points using the overall mean square error
(MSE) was calculated.
To investigate the associations between organ displacement and
bladder and rectum volumes, multilevel modeling methods29 were
used with the intercept coefficient as the random effect and the
slopes (effect of changes of the bladder/rectum) as the fixed effect.
Analysis was done both by considering the bladder and rectum
volumes separately as well as in the same model. The testing level
of significance was set at 0.05. All analyses were done using SAS
version 9.4.
3 | RESULTS
3.A | Volumetric and geometric analysis
Subjects had an average bladder volume increase of 342.4 ± 284%
between initial and final time points (137.26 ± 113.12 cc to
417.2 ± 262.1 cc) and the corresponding change in rectal volume
was ‐6.9 ± 37.7% (102.8 ± 77.2 cc to 102.3 ± 57.9 cc). Figure 2
shows the 3D rendered volumes of the prostate and OARs for sub-
jects 3 (largest rectal volume) and 7 (largest bladder volume), who
also had the largest prostate vector displacements of ~6 mm. The
dominant directions of the shift of the prostate between the bladder
states were in the A‐P direction in both subjects. With reference to
the COM coordinates of the prostate at the final time point, the A‐P
movement of the prostate in subject 3 showed 5.92 and 5.61 mm
displacement (anteriorly) at the second and first time points. The
prostate displacement in subject 7 was 7.75 and 5.81 mm (posteri-
orly) in these two time points.
Table 1 summarizes the statistics for the displacement of the
prostate and SVs between the full and empty bladder states. The
prostate had a dominant vector displacement in the Anterior–Poste-
rior (A‐P) direction, ranging from 1.3 to 5.6 mm across all subjects.
Five of the nine subjects had a prostate displacement of higher than
2 mm along the A‐P direction (three subjects anteriorly and two sub-
jects posteriorly). A significant negative association between the
Superior–Inferior (S‐I) displacement of the prostate centroid with
respect to volume changes in the bladder as well as a positive asso-
ciation with respect to changes in the rectal volume was observed.
In addition, in the A‐P direction, there was a strong positive associa-
tion between changes in the rectal volume and displacement of the
prostate (P = 0.0001). The largest vector displacements were
observed in the SVs (range of 3.1 to 9.3 mm). SVs for all subjects
had >2 mm vector displacement, primarily in A‐P direction (range:
5.2 mm posterior to 7.8 mm anterior), with 7 of the 9 cases shifting
in the anterior direction. In one subject, the S‐I displacement was
dominant with 5.43 mm inferior shift. For the SVs, a strong associa-
tion was observed between the displacement in the A‐P direction
and the rectal volume changes, but no significant association was
found with the bladder volume changes with either cardinal direc-
tion. The same results were also found when both the changes in
bladder and rectum were considered in the same model. Physician
delineations on the T2‐weighted images revealed that the overall
prostate volume change was 1.0% ± 5.5% [range: (−6.4%, 10.3%)]
between the empty and full bladder states.
Additional analyses were done to test whether the centroids for
prostate and SVs change in the same way for changes in bladder
and rectum volumes. For the changes in bladder and rectal volume,
there was no significant difference observed between displacements
in the Left–Right (L‐R) direction for prostate and SVs (P = 0.954 and
P = 0.072, respectively). However, the differences between displace-
ments in the SI and AP directions for prostate and SVs were signifi-
cant (P = 0.0015 and P = 0.008, respectively, for changes in bladder
volume and P = 0.028 and P = 0.028 for changes in the rectum
volume).
3.B | Dosimetric analysis
Figure 3 highlights synthetic CTs for subjects 2 and 5 and their cor-
responding treatment plans that were optimized at the full bladder
state and applied to the empty bladder geometry. Subject 2 had the
highest percent increase of the rectal volume (52% or 71.5 cc) along
with 56% increase in the bladder volume (125 cc) between the two
time points. The prostate shifted posteriorly between the full to
empty state due to the change in bladder and rectal volumes. DVH
analysis revealed a 20.2% reduction in the D95% dose to the PTV
and 22% increase of the D15% dose to the bladder (D15%(TP1) =
80.13 Gy) which is deemed not clinically acceptable.28 However,
the mean dose to the rectum decreased by 11.98% (D15% (TP1) =
2.3 Gy).
Table 2 lists the minimum dose and D95% to the PTV as well as
the D15%, D25%, and D35% to the bladder and rectum, as mea-
sured using the DVH of each of the nine subjects at the bladder full
and bladder empty states. The tables show that the dose delivered
to the PTV is reduced in every subject between the bladder full and
bladder empty states and the dose delivered to the bladder is
increased. Statistical analysis of the dose to the PTV shows that
there is significant difference between the dose to the PTV between
the full and empty bladder states. For change in bladder volumes, all
of the associations with PTV dose measurements are positive and
significant, except for maximum dose. Positive association indicates
that dose to the PTV decreases as the bladder gets smaller. None of
the associations between the changes in rectum volume with PTV
dose measurements were significant. Similar findings were seen
when both the changes in bladder and rectum were included in the
statistical models.
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4 | DISCUSSION
In this work, we did a systematic study of effects of bladder and rec-
tal volumes on displacement of the prostate and surrounding organs
as well as the impact of this displacement on the delivered dose to
the PTV and (OARs). The bladder filling experiment was designed
such that it made possible to model extreme ranges of the bladder
volume and to observe the range of its effects.
Although previous studies seeking to find an optimal bladder
and rectal state30,31 for prostate radiotherapy have not found signif-
icant differences in the intra‐fractional prostate displacement
between plans that were designed for patients with full and empty
bladders, they have not investigated displacement and change in the
dose to the prostate between extreme bladder states. Our results
showed that changes in the bladder volume can lead to large, sys-
tematic displacements in the prostate and SVs. The major displace-
ments are observed in the A‐P and S‐I directions in both organs.
While the prostate is shifted anteriorly in most cases as the bladder
volume is reduced, in some cases, posterior shift is observed. These
findings match the results of a recent study based on analysis of
CBCT and four‐dimensional (4D) trans‐perineal ultrasound (4D
TPUS) measurements of 60 patients that showed intra‐fractional
motion of the prostate in the A‐P and S‐I directions.32 In this study,
reduction of A‐P motion of the prostate was observed when the
planned bladder volume was greater than 200 ml. Also, when the
daily bladder volume was within the third quartiles of the planned
CT volumes, the A‐P and S‐I intra‐fraction displacement of the pros-
tate was reduced.
The major contributor to vector displacements of the prostate
and SVs is the change in bladder volume; however, rectal status/vol-
ume can also contribute to the range of displacements of these
organs, which can be dominant along different axes. This can be
observed in subject 7 (Fig. 2) where the displacement of the prostate
can be related to changes in the rectal volume. In this subject, the
rectal volume reduces in the second time point and increases in the
first time point. Relative to the third time point, the prostate initially
moves posteriorly at the second time point and anteriorly at the first
time point. This matches the results of our statistical analysis which
showed that the rectum volume is the main effector of displacement
of the prostate in the A‐P direction. It should be noted that in our
study, considering the change of rectal gas volume between differ-
ent measurements in some subjects, variations of susceptibility‐
based distortions might affect the measured displacement of the
organs near the rectum. However, previous measurements done
across three magnetic field strengths (1.0, 1.5, and 3.0 T) showed
that only 1.4% and 1.9% of all voxels in the Prostate and SVs were
distorted by greater than 0.5 mm33; therefore we do not expect the
susceptibility‐based distortions to adversely impact our results.
F I G . 2 . Three‐dimensional representation
of the bladder (blue), rectum (red), prostate
(yellow), seminal vesicles (green) and
femoras/pubic bone (cyan) at three bladder
filling time points (TP) for subject 3 (S3)
and subject 7 (S7), who had the largest
prostate displacement between states. The
impact of bladder filling and rectal volume
on the position of the prostate and seminal
vesicles can be observed.
TAB L E 1 Centroid displacement of the prostate and seminal vesicles between initial and final time points for the cohort. Δx, Δy, and Δz
represent displacement of the organ centroids in the LR, AP, and SI directions, respectively. The last two rows reflect the number of subjects
that had an organ center of mass displacement of >2 mm along each axis or as the total vector displacement.
Prostate SVs
Vector (mm) Δx (mm) Δy (mm) Δz (mm) Vector (mm) Δx (mm) Δy (mm) Δz (mm)
Average 3.55 −0.29 1.35 0.61 5.50 −0.24 2.21 1.28
Stdev 1.87 0.62 3.50 2.26 1.67 2.01 3.54 2.87
Min 1.27 −1.19 −5.81 −4.05 3.09 −3.01 −5.20 −5.43
Max 6.10 0.89 5.61 3.36 9.30 3.31 7.81 4.80
# of patients > 2 mm shift 6 0 3 3 9 2 7 4
# of patients < −2 mm shift N/A 0 2 1 N/A 1 1 1
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A previously published CT‐based treatment planning study evalu-
ated the dosimetric impact of full and empty bladders.18 The present
study builds upon this previous work by incorporating MRI across 3–5
time points per subject. MRI has been shown to enable more accurate
and more consistent delineations.34 Further, Moiseenko et al. found that
bladder filling status had limited dosimetric impact on the prostate and
rectal doses; however at that time, treatment planning was conducted
using a four‐field box technique.18 Our work implements much more
conformal treatment planning using arc therapy which showed that
when the bladder volume changes from full to empty, PTV coverage
was adversely affected. Finally, while CT is the gold standard for treat-
ment planning, the present work is the first to evaluate the performance
and dosimetric impact of synthetic CT across varied subject anatomies.
Previous studies have shown that using different table‐top config-
urations used in MRI (i.e., flat and curved couches) may lead to
changes in the relative location of pelvic organs.35 When performing
MRI scans with the patient in treatment position (i.e., using a flat
tabletop similar to the treatment couch vs. a curved diagnostic couch),
more accurate rigid registrations between MR images and CT images
for prostate RT planning has been observed.36 It has also been shown
that during MR‐SIM, the weight of the flexible anterior body coils may
contribute to changes in the position of pelvic organs.34 In this study,
serial imaging data were acquired using a single setup for each subject
(i.e., subjects did not leave the MR table‐top during scanning and no
change in the body coil placements were made during acquisition). By
conducting a within‐subject analysis, the impact of the table‐top selec-
tion and body coils may be considered negligible within a particular
subject. However, in clinical practice, acquiring MRI data in the treat-
ment position improves agreement between the anatomy at time of
treatment planning and during treatment.34
One limitation in the current work is that only nine healthy vol-
unteers were evaluated. Nevertheless, this yielded 34 overall sample
points and enabled statistical comparisons to be made for both
geometry and dosimetry across the target and OARs. Another limita-
tion of this work is that healthy volunteers were evaluated that may
not be representative of the average prostate cancer population.
However, because this work included empty to very full bladder vol-
umes for each subject, we expect that the results, even at intermedi-
ate states, will extend to the prostate cancer population. Another
limitation of this work is that because MR‐CATs were derived from
healthy volunteers, no corresponding CTs were available for quanti-
tative MR‐CAT evaluation. However, a recent study illustrated a
good agreement between MR‐CAT datasets and their corresponding
CTs with a low MAE in a patient cohort.12
In the simulation that we performed, by evaluating the dose deliv-
ered to the organs at the bladder empty state using the treatment plan
optimized for the dose delivered to the PTV at the bladder full state, we
observed that reduction of the bladder size from the full state can lead
F I G . 3 . (Left) Synthetic computed
tomography (CT) images with dose
calculation results for the full and empty
bladder states of subjects 2 and 5, with
the initial plan optimized to the full bladder
geometry. (Right) Dose volume histograms
(DVHs) for the subjects at two bladder
states. A reduction in planning target
volume coverage can be observed due to
the shift of the prostate from the initial
planned location with changes in bladder
and rectal conditions. As expected,
increased bladder dose was also be
observed due to smaller bladder volumes.
This increase is more obvious in S5 where
the bladder dose exceeds the
recommended toxicity level.
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to decreased delivered doses to the PTV and increased dose to the
bladder. Our study did not reveal any significant change in the dose
delivered to the rectum. This simulation further revealed that due to the
shift of the PTV, the dose to the bladder may exceed the maximum rec-
ommended dose to the bladder. Our results confirm the results of
another study by Chen et al. which reported that increases in the blad-
der volume lead to reduction of the dose to the prostate.17 Using CBCT
images of 19 subjects, they found that a 10% increase in bladder volume
leads to 5.6% reduction of mean dose to the prostate. They did not find
significant variations of the rectal volume. These findings contradict a
previous report that although confirming displacement of the prostate
in the A‐P direction after voiding the bladder, found no correlation
between prostate shifts with bladder and rectal volume.18 These results
may be due to that study only evaluating two bladder states (full and
empty), and imaging/contouring was done using CT images. Also, the
reference for prostate motion was based on external fiducial markers.
Considering that contouring the organs might introduce some
uncertainty in their size and position, we eliminated the possible
inter‐observer error by having only one physician delineate the
organs in all subjects, based on the protocol guidelines of RTOG
0815.25 This minimized the differences between the organ contours
for each subject at different time points to ensure isolation of vol-
ume differences and their effects on the organs.
5 | CONCLUSION
Variations in the bladder volume can lead to the displacement of the
prostate which can negatively impact the dose delivered to the PTV
and the bladder. These results show the importance of proper prepa-
ration of patients both for treatment and also during imaging ses-
sions, especially when imaging requires longer scan times such as
MR protocols.
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TAB L E 2 Dose volume histogram (DVH) metrics for the planning target volume (PTV), bladder and rectum for the nine subjects. For each
subject, the top row represents the dose at the bladder empty state and the bottom row the dose at the bladder full state. Mean and standard
deviation of the dose in the initial and final time points across all subjects has been calculated and the bottom row represents the significance
of the difference between these doses in these two time points. Bold‐italized values indicate doses that are outside the accepted range.
Patient Status
PTV Bladder Rectum
Min D (Gy) D95%(Gy) D35%(Gy) D25%(Gy) D15%(Gy) D35%(Gy) D25%(Gy) D15%(Gy)
S1 Empty 14.6 66.9 53.4 61.2 72.5 55.3 68.60 80.53
Full 76.0 79.9 25.3 38.3 54.4 48.7 56.23 69.02
S2 Empty 31.9 62.8 61.6 73.5 80.1 49.7 53.76 60.78
Full 73.2 78.8 40.6 51.3 65.5 51.0 57.75 69.05
S3 Empty 50.3 69.7 60.4 67.1 75.7 40.9 49.78 63.89
Full 73.8 78.7 25.3 39.9 55.2 42.0 49.16 59.96
S4 Empty 28.4 68.9 36.7 49.8 67.8 38.0 43.61 59.13
Full 50.8 76.9 18.2 27.4 50.4 44.4 61.90 77.74
S5 Empty 47.3 72.1 76.8 80.3 81.3 38.9 50.48 73.63
Full 56.9 77.2 53.3 66.5 79.0 37.4 41.45 60.22
S6 Empty 50.3 74.6 74.7 80.4 81.6 41.5 47.11 57.77
Full 69.5 77.6 47.9 51.0 72.8 46.9 55.38 69.33
S7 Empty 30.3 62.9 34.2 44.4 61.1 44.5 54.50 64.03
Full 74.3 79.3 3.4 5.9 24.4 44.0 55.99 72.37
S8 Empty 58.7 71.2 31.2 38.4 47.1 43.4 51.15 63.48
Full 74.1 79.0 4.1 9.1 32.3 37.1 46.22 56.26
S9 Empty 54.6 75.5 78.6 80.4 81.0 52.9 61.52 73.62
Full 72.9 78.7 30.8 41.5 57.1 53.9 63.06 74.48
Mean ± SD Empty 11.8 ± 11.0 69.4 ± 4.3 56.4 ± 17.7 63.9 ± 15.5 72.0 ± 11.0 45.0 ± 5.9 53.39 ± 7.15 66.32 ± 7.33
Full 1.6 ± 1.2 78.5 ± 1.0 27.7 ± 17.6 36.8 ± 19.8 54.6 ± 17.6 45.0 ± 5.4 54.13 ± 6.75 67.60 ± 6.84
P value 0.0003 0.002 <0.0001 <0.0001 <0.0001 0.9919 0.9158 0.9743
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